Symplast lands growth financing to scale aesthetic surgery software

What's the deal? SymplastDealroom has a profile for this one. Try Dealroom →, a Fort Lauderdale-based practice management platform built for plastic surgeons and aesthetic medicine practices, has secured growth financing from Level Structured Capital, a business unit of Level EquityDealroom has a profile for this one. Try Dealroom →. The capital will fund commercial expansion, scaling the sales organisation, and deepening the company's presence in the aesthetic surgery market.

The company did not disclose the financing amount.

Symplast offers a mobile-first, cloud-based platform spanning electronic health records, practice management, CRM, payments, AI-powered workflows, and growth services. Level Structured Capital is a software-focused investor with a track record of backing vertical SaaS leaders.

Why now? The deal arrives as Symplast earned 2026 Best in KLAS recognition for Ambulatory Plastic Surgery Solutions — a prominent industry benchmark. It also coincides with the launch of two marketing campaigns debuting at The Aesthetic Meet 2026, signalling a push to convert product credibility into broader market share.

"This partnership lets us press the accelerator at exactly the right moment," said Facundo Formica, chief executive officer of Symplast. "Our platform is mature. The category is moving. This capital lets us bring Symplast to every aesthetic practice that has been settling for less."

What could go wrong? Aesthetic medicine is a fast-growing cash-pay segment, but it remains a niche. Scaling a vertical SaaS platform means competing for a finite pool of practices, and larger health-tech incumbents could move into the space. Without a disclosed funding figure, it is also hard to gauge how far this capital will stretch.

The signal: Dealroom classifies Symplast as a "breakout" stage company, suggesting it has moved beyond early traction and into a scaling phase — a profile that fits Level Equity's playbook of backing vertical SaaS platforms ready to convert product strength into market dominance. The undisclosed size of the financing makes it harder to benchmark, but the timing — immediately after a Best in KLAS win — points to an investor capitalising on a credibility inflection point to accelerate commercial reach in a niche with limited direct software competition.

Read more: lifestyle.baretnews.com